{
    "nctId": "NCT05300958",
    "briefTitle": "Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer",
    "officialTitle": "Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer: A Single-armed, Phase II Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Objective Response Rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Has measurable metastatic triple-negative breast cancer, with at least 1 measurable lesion per RECIST criteria.\n* Fail second-line or above anti-tumor treatment\n* Evaluation is stable disease with a trend of progression.\n* Minimum life expectancy 16 weeks\n* Histological confirmation of breast cancer on primary tumour at diagnosis/on biopsy of metastasis\n* ECOG Performance Status (PS) 0-2 with no deterioration over previous 2 weeks\n* Normal organ function.\n* Has signed a Patient Informed Consent Form.\n\nExclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) score of \u2265 2\n* Patients with severe liver and kidney insufficiency\n* Deferoxamine Ingredients allergy\n* With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment\n* Inability or unwillingness to comply with study procedures, including inability to take regular oral medication\n* Researchers consider it is not suitable for participation.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}